CYTOKINETICS INC

NASDAQ: CYTK (Cytokinetics, Incorporated)

Last update: 22 May, 5:58AM

60.14

-0.46 (-0.76%)

Market Trend

Short Term Medium Term
Industry Biotechnology (US) Bearish Bullish
Biotechnology (Global) Bearish Bullish
Stock Cytokinetics, Incorporated Bearish Bullish

Stockmoo Consensus

Strong Sell
Sell
Neutral
Buy
Strong Buy

Similar Stocks

Stock Market Cap DY P/E P/B
CYTK 6 B - - -
RARE 4 B - - 23.46
DYN 3 B - - 6.38
ARWR 3 B - - 6.54
DNLI 3 B - - 2.10
FOLD 3 B - - 22.88

Cytokinetics Inc is a biotechnology company that develops muscle biology-driven treatments for diseases characterized by reduced muscle function, muscle weakness, and fatigue. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Sector Healthcare
Industry Biotechnology
Investment Style Small Core
52 Weeks Range
25.98 (-56%) — 110.25 (83%)
Price Target Range
60.00 (-0%) — 106.00 (76%)
High 106.00 (Oppenheimer, 76.26%) Buy
Median 78.00 (29.70%)
Low 60.00 (B of A Securities, -0.23%) Hold
Average 81.44 (35.42%)
Total 8 Buy, 1 Hold
Avg. Price @ Call 50.83
Firm Date Target Price Call Price @ Call
HC Wainwright & Co. 17 Jun 2024 90.00 (49.65%) Buy 52.78
23 May 2024 90.00 (49.65%) Buy 48.98
B. Riley Securities 04 Jun 2024 92.00 (52.98%) Buy 48.41
JMP Securities 31 May 2024 78.00 (29.70%) Buy 48.51
28 May 2024 78.00 (29.70%) Buy 48.21
Truist Securities 29 May 2024 70.00 (16.40%) Buy 47.86
08 Apr 2024 86.00 (43.00%) Buy 74.19
B of A Securities 23 May 2024 60.00 (-0.23%) Hold 48.98
Barclays 23 May 2024 95.00 (57.96%) Buy 48.98
Needham 23 May 2024 72.00 (19.72%) Buy 48.98
14 May 2024 108.00 (79.58%) Buy 59.36
Raymond James 23 May 2024 70.00 (16.40%) Buy 48.98
Oppenheimer 09 May 2024 106.00 (76.26%) Buy 64.02
Show more
Name Avg. Buy ($) Avg. Sell ($) Net Quantity Net Value ($)
BHANJI MUNA - 54.16 -2,000 -108,320
BLUM ROBERT I - 52.78 -22,500 -1,187,550
MALIK FADY IBRAHAM - 53.29 -7,788 -415,023
PARSHALL B LYNNE - 52.78 -5,000 -263,900
Aggregate Net Quantity -37,288
Aggregate Net Value ($) -1,974,793
Aggregate Avg. Buy ($) -
Aggregate Avg. Sell ($) 53.25
Name Holder Date Type Quantity Price Value ($)
BLUM ROBERT I Officer 17 Jun 2024 Sell (-) 22,500 52.78 1,187,550
PARSHALL B LYNNE Director 17 Jun 2024 Sell (-) 5,000 52.78 263,900
PARSHALL B LYNNE Director 17 Jun 2024 Option execute 5,000 - -
MALIK FADY IBRAHAM Officer 11 Jun 2024 Sell (-) 7,788 53.29 415,023
MALIK FADY IBRAHAM Officer 11 Jun 2024 Option execute 5,422 - -
BHANJI MUNA Director 10 Jun 2024 Sell (-) 2,000 54.16 108,320
Date Type Details
17 Jun 2024 Announcement Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
04 Jun 2024 Announcement Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 May 2024 Announcement Cytokinetics to Participate in June Investor Conferences
28 May 2024 Announcement Cytokinetics Announces Closing of Public Offering of Common Stock
22 May 2024 Announcement Cytokinetics Announces Pricing of Public Offering of Common Stock
22 May 2024 Announcement Cytokinetics Announces Proposed Public Offering of Common Stock
22 May 2024 Announcement Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline
17 May 2024 Announcement Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biology
15 May 2024 Announcement Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2024
13 May 2024 Announcement Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress and Published in the New England Journal of Medicine
13 May 2024 Announcement Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress
08 May 2024 Announcement Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586
08 May 2024 Announcement Cytokinetics Reports First Quarter 2024 Financial Results
08 May 2024 Announcement Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic Cardiomyopathy
07 May 2024 Announcement Cytokinetics to Hold Annual Meeting of Stockholders
02 May 2024 Announcement Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
29 Apr 2024 Announcement Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
24 Apr 2024 Announcement Cytokinetics to Announce First Quarter Results on May 8, 2024
10 Apr 2024 Announcement Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 Congress
05 Apr 2024 Announcement Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73ʳᵈ Annual Scientific Session
02 Apr 2024 Announcement Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01 Apr 2024 Announcement Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference
25 Mar 2024 Announcement Cytokinetics Announces Four Upcoming Presentations at the American College of Cardiology 73rd Annual Scientific Session
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No data